Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

2.7%

5 terminated/withdrawn out of 184 trials

Success Rate

97.0%

+10.5% vs industry average

Late-Stage Pipeline

24%

45 trials in Phase 3/4

Results Transparency

41%

66 of 160 completed trials have results

Key Signals

9 recruiting66 with results

Enrollment Performance

Analytics

Phase 1
61(40.9%)
Phase 2
42(28.2%)
Phase 3
30(20.1%)
Phase 4
15(10.1%)
N/A
1(0.7%)
149Total
Phase 1(61)
Phase 2(42)
Phase 3(30)
Phase 4(15)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (184)

Showing 20 of 184 trials
NCT07515014Phase 2Recruiting

A Study of E6742 in Participants With Systemic Lupus Erythematosus

Role: lead

NCT05103904Phase 2Terminated

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Role: collaborator

NCT04572295Phase 1Active Not Recruiting

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Role: lead

NCT03207672Phase 1Active Not Recruiting

Study of E7389 Liposomal Formulation in Participants With Solid Tumor

Role: lead

NCT04238715Phase 2Completed

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Role: lead

NCT06793709Recruiting

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

Role: lead

NCT03833700Phase 1Active Not Recruiting

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Role: lead

NCT04078295Phase 1Active Not Recruiting

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Role: lead

NCT06322667Recruiting

A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

Role: lead

NCT04271488Phase 1Recruiting

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Role: lead

NCT05228158Active Not Recruiting

A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

Role: lead

NCT02275910Phase 1Completed

Phase 1 Study of E7090 in Subjects With Solid Tumor

Role: lead

NCT04568902Phase 1Completed

Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Role: lead

NCT04962867Phase 2Recruiting

NCCH2006/MK010 Trial (FORTUNE Trial)

Role: collaborator

NCT05153941Active Not Recruiting

Diagnosis and Monitoring of Disease Progression Using Deep Neuro Signatures

Role: collaborator

NCT03264547Phase 3Completed

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Role: collaborator

NCT02562118Phase 1Active Not Recruiting

Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer

Role: collaborator

NCT05007392Phase 3Completed

A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout

Role: lead

NCT05181033Phase 2Recruiting

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

Role: collaborator

NCT05594589Phase 2Completed

A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder

Role: lead